US FDA Priority Review for Datopotamab Deruxtecan (Dato-DXd) in Breast Cancer: Phase 3 Clinical Endpoints 2026
Executive Briefing: Regulatory Summary
- Regulatory Action: The US FDA Oncology Center of Excellence (OCE) has accepted the Biologics License Application (sBLA) with Priority Review designation.
- Investigational Agent: Datopotamab Deruxtecan (Dato-DXd), a TROP2-directed topoisomerase I antibody-drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca.
- Target Indication: Adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with systemic therapy.
- Pivotal Trial Milestone: Phase 3 TROPION-Breast01 demonstrated a statistically significant 37% reduction in risk of disease progression or death (HR = 0.63; p < 0.0001).
- Target PDUFA Action Date: Expedited regulatory decision scheduled for mid-2026.
Regulatory & Clinical Trial Specifications
| Regulatory Parameter | Official Specification |
|---|---|
| Therapeutic Molecule | Datopotamab Deruxtecan (Dato-DXd) |
| Drug Class & Target | TROP2-Directed Topoisomerase I ADC |
| Sponsoring Entities | Daiichi Sankyo & AstraZeneca |
| Regulatory Authority | US FDA Oncology Center of Excellence (OCE) |
| Designation Tier | Priority Review (4-Month Timeline Acceleration) |
| Pivotal Phase 3 Study | TROPION-Breast01 (NCT05104866) |
| Progression-Free Survival | Hazard Ratio 0.63 (95% CI: 0.52–0.76; p < 0.0001) |
| Target PDUFA Date | Mid-2026 Decision Target |
1. Regulatory Milestone & Therapeutic Context
The acceptance of the supplemental Biologics License Application (sBLA) under FDA Priority Review marks a pivotal step in precision oncology. Priority Review designation is granted exclusively to investigational therapeutics that offer significant improvements in clinical safety or efficacy over available treatment options.
Antibody-drug conjugates deliver potent cytotoxic payloads directly to tumor cells expressing specific surface antigens while sparing healthy tissues. Datopotamab Deruxtecan targets TROP2, a transmembrane glycoprotein overexpressed in the majority of human breast carcinomas.
2. Pivotal Phase 3 TROPION-Breast01 Clinical Data
The regulatory filing is substantiated by primary analysis findings from the global Phase 3 TROPION-Breast01 trial (NCT05104866) involving over 700 randomized patients:
- Progression-Free Survival (PFS): Dato-DXd achieved a median PFS of 6.9 months compared to 4.9 months in the investigator choice chemotherapy arm, representing a 37% reduction in disease progression or mortality risk.
- Objective Response Rate (ORR): Confirmed ORR reached 36.4% in the Dato-DXd cohort versus 22.9% with conventional systemic chemotherapy.
- Safety Profile: Grade 3 or higher treatment-related adverse events occurred in 21% of Dato-DXd treated patients compared to 45% with chemotherapy. Interstitial lung disease (ILD) Grade 3 or higher was observed in less than 1% of participants.
3. Implications for India’s Clinical Research, SAS & CRO Industry
This major oncology regulatory acceleration directly affects clinical trial analytics and operational staffing across Indian Contract Research Organisations (CROs):
- Clinical SAS Programming: Demand for survival endpoint analysis macros (PROC LIFETEST, PROC PHREG) to construct ADaM time-to-event (ADTTE) datasets and hazard ratio displays.
- Clinical Data Management (CDM): Refined EDC toxicities tracking, specifically monitoring stomatitis grading and blinded independent central review (BICR) data flows.
- Pharmacovigilance (PV): Implementation of targeted Signal Detection and periodic aggregate safety reports (PSUR/PBRER) for conjugated topoisomerase payloads.
Frequently Asked Questions (FAQ)
An ADC binds specifically to the TROP2 antigen on cancer cells and releases its cytotoxic payload inside the cell, thereby reducing systemic tissue toxicity.
Priority Review reduces the FDA evaluation period from 10 months down to 6 months from formal submission, directing specialized agency resources to review the filing.
The target Prescription Drug User Fee Act (PDUFA) action date is targeted for mid-2026, following assessment by the FDA Oncology Center of Excellence.
Related Regulatory & Clinical Intelligence Keywords
Datopotamab Deruxtecan
Dato-DXd ADC
TROP2 Targeted Therapy
Metastatic Breast Cancer
Phase 3 TROPION-Breast01
Progression-Free Survival
PDUFA Target Date
Clinical SAS ADTTE
BICR Radiological Review
Topoisomerase I Inhibitor
Oncology Center of Excellence
CRO Trial Operations
CDISC Standards
AstraZeneca Daiichi Sankyo
Precision Oncology 2026